Early Postoperative Endoscopic Recurrence in Crohn's Disease Is Characterised by Distinct Microbiota Recolonisation.


Journal

Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676

Informations de publication

Date de publication:
07 Nov 2020
Historique:
pubmed: 26 4 2020
medline: 7 9 2021
entrez: 26 4 2020
Statut: ppublish

Résumé

Intestinal microbiota dysbiosis is implicated in Crohn's disease [CD] and may play an important role in triggering postoperative disease recurrence [POR]. We prospectively studied faecal and mucosal microbial recolonisation following ileocaecal resection to identify the predictive value of recurrence-related microbiota. Mucosal and/or faecal samples from 121 CD patients undergoing ileocaecal resection were collected at predefined time points before and after surgery. Ileal biopsies were collected from 39 healthy controls. POR was defined by a Rutgeerts score ≥i2b. The microbiota was evaluated by 16S rRNA sequencing. Prediction analysis was performed using C5.0 and Random Forest algorithms. The mucosa-associated microbiota in CD patients was characterised by a depletion of butyrate-producing species (false discovery rate [FDR] <0.01) and enrichment of Proteobacteria [FDR = 0.009] and Akkermansia spp. [FDR = 0.02]. Following resection, a mucosal enrichment of Lachnospiraceae [FDR <0.001] was seen in all patients but in POR patients, also Fusobacteriaceae [FDR <0.001] increased compared with baseline. Patients without POR showed a decrease of Streptococcaceae [FDR = 0.003] and Actinomycineae [FDR = 0.06]. The mucosa-associated microbiota profile had good discriminative power to predict POR, and was superior to clinical risk factors. At Month 6, patients experiencing POR had a higher abundance of taxa belonging to Negativicutes [FDR = 0.04] and Fusobacteria [FDR = 0.04] compared with patients without POR. Microbiota recolonisation after ileocaecal resection is different between recurrence and non-recurrence patients, with Fusobacteria as the most prominent player driving early POR. These bacteria involved in the early recolonisation and POR represent a promising therapeutic strategy in the prevention of disease recurrence.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Intestinal microbiota dysbiosis is implicated in Crohn's disease [CD] and may play an important role in triggering postoperative disease recurrence [POR]. We prospectively studied faecal and mucosal microbial recolonisation following ileocaecal resection to identify the predictive value of recurrence-related microbiota.
METHODS METHODS
Mucosal and/or faecal samples from 121 CD patients undergoing ileocaecal resection were collected at predefined time points before and after surgery. Ileal biopsies were collected from 39 healthy controls. POR was defined by a Rutgeerts score ≥i2b. The microbiota was evaluated by 16S rRNA sequencing. Prediction analysis was performed using C5.0 and Random Forest algorithms.
RESULTS RESULTS
The mucosa-associated microbiota in CD patients was characterised by a depletion of butyrate-producing species (false discovery rate [FDR] <0.01) and enrichment of Proteobacteria [FDR = 0.009] and Akkermansia spp. [FDR = 0.02]. Following resection, a mucosal enrichment of Lachnospiraceae [FDR <0.001] was seen in all patients but in POR patients, also Fusobacteriaceae [FDR <0.001] increased compared with baseline. Patients without POR showed a decrease of Streptococcaceae [FDR = 0.003] and Actinomycineae [FDR = 0.06]. The mucosa-associated microbiota profile had good discriminative power to predict POR, and was superior to clinical risk factors. At Month 6, patients experiencing POR had a higher abundance of taxa belonging to Negativicutes [FDR = 0.04] and Fusobacteria [FDR = 0.04] compared with patients without POR.
CONCLUSIONS CONCLUSIONS
Microbiota recolonisation after ileocaecal resection is different between recurrence and non-recurrence patients, with Fusobacteria as the most prominent player driving early POR. These bacteria involved in the early recolonisation and POR represent a promising therapeutic strategy in the prevention of disease recurrence.

Identifiants

pubmed: 32333762
pii: 5825267
doi: 10.1093/ecco-jcc/jjaa081
pmc: PMC7648170
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1535-1546

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.

Références

Appl Environ Microbiol. 2001 Oct;67(10):4399-406
pubmed: 11571135
Gut. 2017 May;66(5):813-822
pubmed: 28179361
Cell Rep. 2017 Apr 25;19(4):733-745
pubmed: 28445725
Gastroenterol Clin North Am. 2004 Jun;33(2):347-60, x
pubmed: 15177543
Best Pract Res Clin Gastroenterol. 2013 Feb;27(1):47-58
pubmed: 23768552
Gastroenterology. 2005 Apr;128(4):856-61
pubmed: 15825069
Appl Environ Microbiol. 2015 Jun;81(11):3655-62
pubmed: 25795669
J Crohns Colitis. 2017 Feb;11(2):191-203
pubmed: 27466174
Lancet. 1991 Sep 28;338(8770):771-4
pubmed: 1681159
Inflamm Bowel Dis. 2013 Mar;19(3):481-8
pubmed: 23385241
Inflamm Bowel Dis. 2018 Mar 19;24(4):861-870
pubmed: 29562272
Cell Host Microbe. 2014 Mar 12;15(3):382-392
pubmed: 24629344
Gastroenterology. 2008 Oct;135(4):1123-9
pubmed: 18727929
Aliment Pharmacol Ther. 2004 May 15;19(10):1073-8
pubmed: 15142196
Sci Rep. 2018 Jun 27;8(1):9734
pubmed: 29950676
Anaerobe. 2015 Feb;31:15-8
pubmed: 25157873
BMC Gastroenterol. 2013 Aug 22;13:131
pubmed: 23964800
Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16731-6
pubmed: 18936492
Inflamm Bowel Dis. 2012 Apr;18(4):758-77
pubmed: 21830279
Appl Environ Microbiol. 2009 May;75(10):3250-7
pubmed: 19286780
Microbiome. 2018 Dec 17;6(1):226
pubmed: 30558668
Tumour Biol. 2016 Mar;37(3):2805-10
pubmed: 26718210
Bioinformatics. 2010 Oct 1;26(19):2460-1
pubmed: 20709691
Tissue Barriers. 2015 Apr 03;3(1-2):e982426
pubmed: 25838985
Gut. 2006 Feb;55(2):205-11
pubmed: 16188921
Biochim Biophys Acta. 2005 Jul 30;1713(2):92-112
pubmed: 15993836
Int J Antimicrob Agents. 2013 Feb;41(2):149-55
pubmed: 23294932
Inflamm Bowel Dis. 2015 Jun;21(6):1219-28
pubmed: 25844959
Gastroenterology. 2014 May;146(6):1489-99
pubmed: 24560869
Gut. 2020 Mar;69(3):462-472
pubmed: 31142586
Nat Rev Microbiol. 2012 Jun 25;10(8):575-82
pubmed: 22728587
Gastroenterology. 2017 Feb;152(2):327-339.e4
pubmed: 27769810
Gut. 2011 May;60(5):631-7
pubmed: 21209126
Inflamm Bowel Dis. 2015 Dec;21(12):2839-47
pubmed: 26296064
IEEE/ACM Trans Comput Biol Bioinform. 2019 Nov-Dec;16(6):2078-2088
pubmed: 29994028
Gut. 2016 Jun;65(6):954-62
pubmed: 26628508
Am J Gastroenterol. 2002 Apr;97(4):939-46
pubmed: 12003430
Am J Gastroenterol. 2010 Nov;105(11):2420-8
pubmed: 20648002
World J Gastroenterol. 2017 Jul 7;23(25):4548-4558
pubmed: 28740343
PLoS One. 2013 Sep 10;8(9):e74963
pubmed: 24040367
J Gastroenterol Hepatol. 2015 Feb;30(2):268-78
pubmed: 25087692
Gastroenterology. 2004 Aug;127(2):412-21
pubmed: 15300573
Infect Immun. 2011 Jul;79(7):2597-607
pubmed: 21536792
Nutrients. 2018 Jul 29;10(8):
pubmed: 30060606
Genome Res. 2012 Feb;22(2):292-8
pubmed: 22009990
Gastroenterology. 1995 Jun;108(6):1617-21
pubmed: 7768364
Gastroenterology. 1990 Oct;99(4):956-63
pubmed: 2394349
Clin Colon Rectal Surg. 2018 May;31(3):168-178
pubmed: 29720903
Biometrics. 2006 Jun;62(2):361-71
pubmed: 16918900
Lancet. 2017 Mar 25;389(10075):1218-1228
pubmed: 28214091
BMC Microbiol. 2014 May 01;14:112
pubmed: 24884524

Auteurs

Kathleen Machiels (K)

Department of Chronic Diseases Metabolism and Ageing, KU Leuven, Leuven, Belgium.

Marta Pozuelo Del Río (M)

Department of Gastroenterology, Vall d'Hebron Research Institute, Barcelona, Spain.

Adrian Martinez-De la Torre (A)

Department of Gastroenterology, Vall d'Hebron Research Institute, Barcelona, Spain.

Zixuan Xie (Z)

Department of Gastroenterology, Vall d'Hebron Research Institute, Barcelona, Spain.

Victòria Pascal Andreu (V)

Department of Gastroenterology, Vall d'Hebron Research Institute, Barcelona, Spain.

João Sabino (J)

Department of Chronic Diseases Metabolism and Ageing, KU Leuven, Leuven, Belgium.
Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.

Alba Santiago (A)

Department of Gastroenterology, Vall d'Hebron Research Institute, Barcelona, Spain.

David Campos (D)

Department of Gastroenterology, Vall d'Hebron Research Institute, Barcelona, Spain.

Albert Wolthuis (A)

Department of Abdominal Surgery, University Hospitals Leuven, Leuven, Belgium.

André D'Hoore (A)

Department of Abdominal Surgery, University Hospitals Leuven, Leuven, Belgium.

Gert De Hertogh (G)

Department of Imaging & Pathology, KU Leuven, Leuven, Belgium.

Marc Ferrante (M)

Department of Chronic Diseases Metabolism and Ageing, KU Leuven, Leuven, Belgium.
Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.

Chaysavanh Manichanh (C)

Department of Gastroenterology, Vall d'Hebron Research Institute, Barcelona, Spain.
CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.

Séverine Vermeire (S)

Department of Chronic Diseases Metabolism and Ageing, KU Leuven, Leuven, Belgium.
Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH